Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.0100 (6.46%) ($12.7700 - $14.0100) on Thu. Jun. 18, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.6% (three month average) | RSI | 60 | Latest Price | $14.0100(6.46%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 5% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -2.3% in a week (0% probabilities). VIXM(-28%) VXX(-14%) UUP(-11%) UNG(-4%) TLT(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.3% (StdDev 4.6%) | Hourly BBV | 0 () | Intraday Trend | 8.4% | | | |
|
5 Day Moving Average | $12.46(12.44%) | 10 Day Moving Average | $12.25(14.37%) | 20 Day Moving Average | $12.41(12.89%) | To recent high | 0% | To recent low | 69% | Market Cap | $3.618b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |